WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership

WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration withNatural Cycles°(NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with...
Anglais

Kioxia Showcases Flash Storage Innovations for the AI Era at FMS 2026

Kioxia group, a world leader in memory solutions, will demonstrate how its flash memory and SSD technologies, including the KIOXIA GP1 Series PCIe® 6.0 NVMe™ Super High IOPS SSDs, optimized for GPU direct access, are enabling the next generation of AI infrastructure at FMS: the Future of Memory and Storage, taking place August 4–6 in Santa Clara, California. Through a keynote presentation, executive panel discussions, technical sessions, and technology demonstrations, Kioxia...
Anglais

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD)...
Anglais

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 25

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to...
Anglais

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care

LabPMM®, an Invivoscribe®subsidiary, today announced the global availability of its newKMT2Ameasurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing...
Anglais
Subscribe to The Agency